The care triangle: Determining the gaps in the management of atopic dermatitis

Journal of Cutaneous Medicine and Surgery

Volumn 17, Issue 4, 2013, Pages 276-282

  O'Toole, Ashley ^a,b   Thomas, Bjorn ^b,c   Thomas, Richard ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; EMOLLIENT AGENT; METHOTREXATE; PIMECROLIMUS; PREDNISONE; TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; COST EFFECTIVENESS ANALYSIS; DERMATOLOGIST; DRUG COST; EVIDENCE BASED MEDICINE; EXPERIENCE; HEALTH CARE; HEALTH CARE NEED; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN BURNING SENSATION; SKIN INFECTION;

DERMATITIS, ATOPIC; HUMANS;

EID: 84883201197     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2013.12119     Document Type: Article

References (41)

1. Shear N,Vender R, Thomas R. Eczema treatment: treatment triangle. Skin Ther Lett. 2012. Available at: http://www.skintherapyletter.com/treat/eczema/ treatment-triangle.html (accessed November 11, 2012).
2. Guyatt G, Cairns J, Churchill D, et al. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA, 268:2420-5, doi:10.1001/ jama.1992.03490170092032.
3. Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I. Treatment of skin disease: comprehensive therapeutic strategies. 3rd ed. London: Saunders Elsevier; 2010.
4. Thomas K, Bath-Hextall F, Ravenscroft J, et al. Atopic eczema. In: Williams H, editor. Evidence-based dermatology. 2nd ed. Oxford (UK): Blackwell Publishing; 2009. p. 465-78.
5. Thomas R, Landells I, Lynde C, et al. Canadian consensus paper on skin barrier repair therapy in atopic dermatitis. J Cutan Med Surg 2012;16 Suppl 1:S1-15.
6. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe atopic dermatitis. J Drugs Dermatol 2009;8:1106-11.
7. Hughes J, Rustin M. Corticosteroids. Clin Dermatol 1997;15:715- 21, doi:10.1016/S0738-081X(97)00020-5.
8. Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol 2005;152:130-41, doi:10.1111/ j.1365-2133.2005.06410.x.
9. Pershing LK, Corlett JL, Lambert LD, Poncelet CE. Circadian activity of topical 0.05% betamethasone dipropionate in human skin in vivo. J Investig Dermatol 1994;102:734-9, doi:10.1111/ 1523-1747.ep12376062.
10. Van der Meer JB, Glazenburg EJ, Mulder PGH, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999;140:1114-21, doi:10.1046/j.1365-2133.1999.02893. x.
11. Berth-Jones J, Damstra RJ, Golsh S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomized, double blind, parallel group study. BMJ 2003;326:1367, doi:10.1136/bmj.326. 7403.1367.
12. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone proprionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2003;147:528-37, doi:10.1046/j.1365-2133.2002.05006.x.
13. Healy E, Bentley A, Fidler C, Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol 2011;164:387-95, doi:10.1111/j.1365-2133. 2010.10141.x.
14. Ellis CN, Drake LA, Prendergast MM, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003;48:553-63, doi:10.1067/mjd.2003.240.
15. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic dermatitis. Health Technol Assess 2000;4:1.
16. Valkova S, Velkova A. UVA/UVB phototherapy for atopic dermatitis revisited. J Dermatolog Treat 2004;15:239-44, doi:10.1080/09546630410035338.
17. Kelsay K. Management of sleep disturbance associated with atopic dermatitis. J Allergy Clin Immunol 2006;118:198-201, doi:10.1016/ j.jaci.2006.04.038.
18. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol 2010;163:12-26, doi:10.1111/j.1365-2133.2010. 09727.x.
19. Gotzsche PC, Johansen HK, Schmidt LM, Burr ML. House dust mite control measures for asthma. Cochrane Database Syst Rev 2004;(4):CD001187.
20. Charman C. Atopic eczema. In: Godley F, editor. Clinical evidence. London: BMJ Publishing Group; 2001. p. 1133-45.
21. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr 2003;36:223-7, doi:10.1097/ 00005176-200302000-00012.
22. Probiotics for atopic disease. Drug Ther Bull 2005;43:6-8, doi:10.1136/dtb.2005.4316. 23.
23. Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am J Clin Dermatol 2008;9:93-103, doi:10.2165/00128071- 200809020-00002.
24. Armstrong NC, Ernst E. The treatment of eczema with Chinese herbs: a systematic review of randomized clinical trials. Br J Clin Pharmacol 1999;48:262-4, doi:10.1046/j.1365-2125.1999.00004.x.
25. Anderson PH, Bindslev-Jensen C, Mosbech H, et al. Skin symptoms in patients with atopic dermatitis using enzyme containing detergents. A placebo-controlled study. Acta Derm Venereol 1998;78:60-2, doi:10.1080/ 00015559850135878.
26. Thomas KS, Koller K, Dean T, et al. A multicentre randomised controlled trial and economic evaluation of ion-exchange water softeners for the treatment of eczema in children: the Softened Water Eczema Trial (SWET). Health Technol Assess 2011;15 (8:)v-vi, 1-156.
27. Wolfe B, Tan J, Sirois F. Psoriasis patients' experiences at diagnosis: a qualitative analysis. Proceedings of the 85th Annual Canadian Dermatology Association Conference; 2010 June 26-30; St John's Newfoundland.
28. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860-76, doi:10.1067/mai.2000.106484.
29. Elias PM, Wood LC, Feingold KR. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermatitis 1999;10:119- 26, doi:10.1016/S1046-199X(99) 90054-4.
30. Hodari KT, Nanton JR, Carroll CL, et al. Adherence in dermatology: a review of the last 20 years. J Dermatolog Treat 2006;17:136-42, doi:10.1080/09546630600688515.
31. Evers AW, Kleinpenning MM, Smits T, et al. Treatment nonadherence and long-term effects of narrow band UV-B therapy in patients with psoriasis. Arch Dermatol 2010;146:198-9, doi:10.1001/archdermatol.2009.382.
32. Van de Kerkhof PCM, de Hoop D, de Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200:292-8, doi:10.1159/ 000018390.
33. Lott R, Taylor SL, O'Neill JL, et al. Medication adherence among acne patients: a review. J Cosmet Dermatol 2010;9:160-6, doi:10.1111/j.1473-2165. 2010.00490.x.
34. Zaghloul SS, Goodfield MJD. Assessment of compliance with psoriasis treatment. Arch Dermatol 2004;140:408-14, doi:10.1001/ archderm.140.4.408.
35. Baldwin HE. Tricks for improving compliance with acne therapy. Dermatol Ther 2006;19:224-36, doi:10.1111/j.1529-8019.2006. 00078.x.
36. Gokdemir G, Ari S, Koslü A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol 2008;22:330-5, doi:10.1111/j.1468-3083.2007. 02425.x.
37. Yentzer BA, Camacho FT, Young T, et al. Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance. J Drugs Dermatol 2010;9:324-9.
38. Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis 2010;B6:103-8.
39. Gupta G, Mallefat P, Kress DW, Sergeant A. Adherence to topical dermatological therapy: lessons from oral drug treatment. BMJ 2009;161:221-7.
40. Josine de Bes CM, Legierse AC, de Korte P. Patient education in chronic skin diseases: a systematic review. Acta Derm Venereol 2011;91:12-7.
41. Tan J, Stacey D, Fung K, et al. Treatment decision needs of psoriasis patients: cross-sectional survey. J Cutan Med Surg 2010; 15:233-9.